Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
Exposures Product Safety
What's Going On Johnson & Johnson Stock Today?
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch. 
Via Benzinga
Topics Earnings
Exposures Financial
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Johnson & Johnson Stock Was Pulling Back Today
The healthcare giant matched estimates, but it wasn't enough to please investors. 
Via The Motley Fool
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Stocks To Consider After Beating Earnings Estimates
With the earnings season now in full force, valuable data to gauge the broader economy will be rolling in. I will share three stocks that posted earnings beats this morning, and that I think may be... 
Via Talk Markets
Topics Earnings Economy
Exposures Economy Financial
Your Guide To Volatile Earnings This Week - NFLX On The Move
This week we get to play some earnings trades as earnings season begins for 2024. We're seeing Netflix rally immediately after hours on its earnings as we plot its expected move for tomorrow and... 
Via Talk Markets
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
JNJ earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
US Stocks Pause As Treasury Yields, Dollar Surge On Trimmed Fed Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street took a breather on Tuesday, with the major U.S. stock indices trading near the flatline or showing slight declines during midday trading in New York as investors closely await a series of... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Johnson & Johnson's Settlement For Talc Cancer Lawsuits Reaches $700M Settlement With US States
Johnson & Johnson settles state investigations for $700 million, addressing alleged talc product safety issues linked to cancer. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
What's Going On With Danish Healthcare Firm Genmab Stock?
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Mixed; Johnson & Johnson Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 90 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 37,915.41 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson's Clock 12% Q4 Revenue Growth, Cancer and Crohn's Disease Drugs Account as Largest Sellers
Johnson & Johnson's Q4 2023 performance, with adjusted earnings up 11.7%, sales at $21.4 billion, and key insights into pharmaceutical and MedTech segments. 
Via Benzinga
Why J&J's Narrow Fourth-Quarter Beat Is A Blessing For Medtech
The company's medtech sales easily beat expectations, which bodes well for medtech stocks. 
Via Investor's Business Daily
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 personal care stocks that smell like good earnings plays
Management remarks about how they plan to use technology to drive growth could matter just as much as near-term financials for these personal care companies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
US Stocks Prepare For Nervy Start Ahead of Netflix, TI Earnings: Analyst Says Cash Waiting On Sidelines Could Flood Street If This Happens
The mood turned circumspect on Tuesday as traders digested a deluge of earnings reports and anticipated market-moving economic data for the week. 
Via Benzinga
Johnson & Johnson Surpasses $2.28 EPS Expectation in Q4
Johnson & Johnson exceeded the anticipated earnings per share (EPS) of $2.28, showcasing operational efficiency and resilience in a complex global business environment. 
Via Talk Markets
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
From Johnson & Johnson
Via Business Wire
2 Genius Safe Stocks to Buy for 2024 and Beyond
These companies have considerable profits and tried-and-true dividends in common. 
Via The Motley Fool
Earnings Scheduled For January 23, 2024
Companies Reporting Before The Bell • Webster Finl (NYSE:WBS) is estimated to report quarterly earnings at $1.46 per share on revenue of $603.11 million. 
Via Benzinga
Fear & Greed Index Remains In 'Greed' Zone; Dow Settles Above 38,000
The CNN Money Fear and Greed index remained in the "Greed" zone on Monday. U.S. stocks closed higher on Monday, with the Dow Jones index settling above the 38,000 mark for the first time. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verizon, Netflix And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Dow Jones Stocks: From 3M To Intel, A Big Earnings Week For Blue Chips
Eight Dow Jones stock report earnings this week. Several, including Verizon and 3M, are in buy zones or near buy points. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.